Trial Profile
A phase III study of Fluorine-18-MK-6240
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 05 Dec 2023
Price :
$35
*
At a glance
- Drugs Florquinitau F18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- 10 Jan 2017 New trial record
- 05 Jan 2017 According to a Cerveau Technologies media release, the company plans to initiate this study in early 2018.